• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Genetic screening for gynecological cancer: where are we heading? 
    •   QMRO Home
    • Barts Cancer Institute
    • Centre for Experimental Cancer Medicine
    • Genetic screening for gynecological cancer: where are we heading?
    •   QMRO Home
    • Barts Cancer Institute
    • Centre for Experimental Cancer Medicine
    • Genetic screening for gynecological cancer: where are we heading?
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Genetic screening for gynecological cancer: where are we heading?

    View/Open
    Accepted version (250.9Kb)
    Volume
    12
    Pagination
    207 - 220
    DOI
    10.2217/fon.15.278
    Journal
    Future Oncol
    Issue
    2
    Metadata
    Show full item record
    Abstract
    The landscape of cancer genetics in gynecological oncology is rapidly changing. The traditional family history-based approach has limitations and misses >50% mutation carriers. This is now being replaced by population-based approaches. The need for changing the clinical paradigm from family history-based to population-based BRCA1/BRCA2 testing in Ashkenazi Jews is supported by data that demonstrate population-based BRCA1/BRCA2 testing does not cause psychological harm and is cost effective. This article covers various genetic testing strategies for gynecological cancers, including population-based approaches, panel and direct-to-consumer testing as well as the need for innovative approaches to genetic counseling. Advances in genetic testing technology and computational analytics have facilitated an integrated systems medicine approach, providing increasing potential for population-based genetic testing, risk stratification, and cancer prevention. Genomic information along-with biological/computational tools will be used to deliver predictive, preventive, personalized and participatory (P4) and precision medicine in the future.
    Authors
    Manchanda, R; Jacobs, I
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/10784
    Collections
    • Centre for Experimental Cancer Medicine [130]
    Language
    eng
    Copyright statements
    Future Medicine Ltd

    Related items

    Showing items related by title, author, creator and subject.

    • Genetic dysbiosis: How host genetic variants may affect microbial biofilms 

      Nibali, L (2016-09-22)
      © 2016 by John Wiley & Sons, Inc. All rights reserved. A sensible hypothesis is that host genetic variants affect not only the individual ability to respond to microbial challenges, thus predisposing to the onset of acute ...
    • Discovery in Genetic Skin Disease: The Impact of High Throughput Genetic Technologies 

      Maruthappu, T; Scott, CA; Kelsell, DP (2014-09)
    • A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population 

      Marzec, J; Mao, X; Li, M; Wang, M; Feng, N; Gou, X; Wang, G; Sun, Z; Xu, J; Xu, H (2016-04-19)
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.